News
Public · Published
US estrogen supply crunch widens as women seek alternatives to scarce patches
Women in the US face shortages of estrogen patches and also some injectable and vaginal estrogen products as demand rises. The FDA has worked with manufacturers since September to boost patch supplies, and pharmacies report problems with other forms of the hormone.
Published:
Updated:
What happened
Women in the US face shortages of estrogen patches and also some injectable and vaginal estrogen products as demand rises. The FDA has worked with manufacturers since September to boost patch supplies, and pharmacies report problems with other forms of the hormone.
Confirmed
Global impact / market context
Limited estrogen supplies can push women to switch products or go without treatment for menopause symptoms. For drugmakers, sustained demand and backorders can shift revenue between products and raise pressure to expand manufacturing capacity, which is spending on factories and equipment.
Analyst inference
Hormone therapy demand rose after the FDA removed a long-standing boxed warning, which is a prominent safety notice, on some products last year. Shortages now extend beyond patches to injections and vaginal creams, suggesting supply constraints are spreading across multiple manufacturers and product types.
Analyst inference
What to watch
- The American Society of Health-System Pharmacists listed estradiol injection products from Hikma, American Regent and Par Sterile Products as in shortage early in September. Confirmed
- ASHP lists vaginal estradiol creams made by Viatris' Mylan unit, Padagis and Teva as on backorder or allocation, meaning supply is limited. Confirmed
- Watch whether women switching from scarce patches keep straining injections and creams, and whether manufacturers add production capacity or the FDA takes further steps to ease shortages. Analyst inference
Evidence
- Original source link unavailable